Pilot BCR-ABL1 Minor Quantification (Not Accredited)

 

BCR-ABL1 rearrangements at the minor breakpoint cluster region (m-BCR), leading to production of the p190 fusion protein, are most frequently associated with Ph-positive Acute Lymphocytic Leukaemia (ALL) and a small subset of Chronic Myeloid Leukaemia (CML) patients. Quantification of minor BCR-ABL1 transcript levels can be utilised to monitor patient response to treatment and disease recurrence.

 

In this new pilot programme for 2014/15, participants are provided with lyophilised cell line material for quantitative analysis of the BCR-ABL1 minor transcript. Participants are asked to submit quantitative results as %BCR-ABL1/control gene together with details of their methodology. Instructions for the storage, reconstitution and use of the lyophilised samples are included with each sample send-out. Two distributions are issued per annum, with each send-out consisting of two samples.

 

No activities in relation to this EQA programme are subcontracted.

 

To register for this programme, please click here.

Example BCR-ABL1 Minor Quantification Report
Trial mBCRQ 151602 v1.0.0 Report Example[...]
Adobe Acrobat document [1.6 MB]
Example BCR-ABL1 Minor Results Form
mBCRQ 171801 results form.pdf
Adobe Acrobat document [112.9 KB]
Print Print | Sitemap

Follow Us Online!
Facebook Twitter LinkedIn Youtube

Disclaimer

Last updated 27th September 2017 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information, please click here.


The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).